Phigenix

Phigenix is a privately held U.S. precision oncology company developing cancer diagnostics and targeted therapeutics, with an emphasis on prostate and breast cancer. The company states that it is building a personalized medicine platform around the detection and targeting of the PAX2 and EN2 oncogenes, alongside therapeutic strategies involving Human beta-defensin 1 (DEFB1). Its pipeline appears to include companion and early-detection diagnostics, targeted drugs and antibodies including antibody-drug conjugates, and an mRNA-based cancer vaccine concept. Publicly available information indicates the company remains at an early, largely preclinical stage rather than in active late-stage clinical development. Phigenix is headquartered in Atlanta, Georgia and was founded by Carlton D. Donald.